1Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
2Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Copyright © 2019 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
Modified from Tsilidis et al. [10].
CI, confidence interval.
Drug class | Clinical evidence on cancer | Reference |
---|---|---|
Sodium glucose cotransporter 2 inhibitors | Safe with currently available data, further studies are needed | [4647] |
Incretin-based drugs | Safe with currently available data, further studies are needed | [14484950515253] |
Thiazolidinediones | Neutral except bladder cancer risk | [111254555657585960616263] |
Sulfonylureas | Neutral | [1114656667] |
Metformin | Neutral maybe beneficial | [6468697071] |
Insulin analogue | Neutral | [111233727374757677] |
Role of αVβ3 in Prostate Cancer: Metastasis Initiator and Important Therapeutic Target